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KEY POINTS
 Interval colorectal cancers (CRCs) may account for approximately half of all CRCs identi-
fied during IBD surveillance, which highlights the need for improvements.
 The cause of interval CRCs is multifactorial, with procedural factors likely to play an impor-
tant role.
 Molecular events promoted by inflamed mucosa may augment the cancer risk and
perhaps explain some interval CRCs.The past decade has witnessed considerable progress in the management of inflam-
matory bowel disease (IBD), including improvements in the quality and effectiveness
of colonoscopic surveillance.1–3 Patients with ulcerative colitis (UC) or Crohn’s colitis
have a greater risk of colorectal cancers (CRC), which may develop earlier and prog-
ressmore rapidly than sporadic CRCs. Althoughmost societies now endorse intensive
colonoscopic surveillance to reduce the CRC risk,4–6 the efficacy of this strategy re-
mains controversial. Several recent studies have cast doubt about the limited effective-
ness of colonoscopy at reducing the incidence of sporadic CRC in the general
population, especially in the proximal part of the colon,7,8 resulting in the occurrence
of interval CRCs. Little is known, however, about the magnitude of this problem in pa-
tients with IBD and the most common explanations. Similar to the sporadic interval
CRCs, two factors contribute to interval CRCs in IBD: clinician-dependent factors,
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Sanduleanu & Rutter338molecular features of the inflamed mucosa underlying the development of cancer. The
endoscopic knowledge, equipment, and techniques have evolved in recent years,
contributing to a paradigm shift in the diagnosis and endoscopic resection of CRC pre-
cursors. The nonpolypoid (flat or depressed) colorectal neoplasms (NP-CRNs) play a
significant role in the genesis of interval CRCs.9 Such subtle-appearing lesions are
indeedmore likely missed or incompletely resected endoscopically than their polypoid
counterparts, and a subgroup of them harbor an aggressive biologic behavior.
This article provides insight into the magnitude andmost common factors underlying
the cause of interval CRCs during surveillance for IBD. Milestones of the literature
regardingCRC risk inpatientswith IBDare reviewed.Specifically examined to theoccur-
rence of interval CRCs are the contribution ofmissed, incompletely resected lesions; the
adherence to surveillance; and distinct biologic features of the inflamed mucosa. Key
principles are presented for ensuring the quality of IBD surveillance practice.INCIDENCE OF CRC AND INTERVAL CRC
A casual glance at the overall incidence of CRC in patients with IBD reveals discrepant
outcomes, with a few studies showing similar CRC rates in patients with IBD versus
the general population,10,11 whereas others show greater rates.12–14 In a nationwide
cohort of close to 50,000 Danish patients with IBD who were followed over
three decades (1979–2008), CRC was identified in 338 (0.71%) cases (268 in patients
with UC and 70 in patients with Crohn’s disease).10 The overall CRC risk among pa-
tients with UC in this study was similar to that of the general population (relative
risk, 1.07; 95% confidence interval, 0.95–1.21). In contrast, a North American study15
conducted from 1998 through 2010 found that the incidence of CRC in patients with
Crohn’s disease or UC was 60% higher than in the general population.
The Danish study found a marked decline in the overall relative risk of CRC among
patients with UC over the past decades, from 1.34 (95% confidence interval, 1.13–
1.58) in 1979 to 1988 to 0.57 (95% confidence interval, 0.41–0.80) in 1999 to
2008,10 possibly reflecting refinements in the anti-inflammatory arsenal (ie, immuno-
suppressive therapy, biologicals), but perhaps also caused by a gradual adoption of
CRC screening and surveillance. Conversely, the North American study15 found a
fairly stable CRC rate in patients with IBD over time. Controversies surrounding the
time-trends in CRC risk are not surprising, and likely reflect the cumulative effect of
several factors, such as advancements in endoscope technology, a greater aware-
ness, and improvements in the quality of colonoscopic performance.
As a common denominator, such epidemiologic studies lack relevant information
about the disease duration, degree and extent of inflammation, presence of risk fac-
tors (ie, primary sclerosing cholangitis, personal or family history of CRC), and patients’
compliance with the recommended follow-up. Although clinical studies provide such
details, most have focused on the optimal frequency of surveillance, paying less atten-
tion to the quality of examination. A systematic characterization of the lesions pheno-
type, in particular the location, size, shape, and histology, is often lacking.
Very few data are available about the occurrence of interval cancers during surveil-
lance for IBD. The first paper dates back to 1982.16 In this surgical review of 676 pa-
tients with UC undergoing long-term follow-up, a total of 35 CRCs were identified.
Twelve of these were diagnosed because of symptoms, 10 as incidental findings at
proctocolectomy, and 13 CRCs were diagnosed during the follow-up at least 1 year
after the initial UC diagnosis. This latter subgroup was referred to as “interval
CRCs.” In a St Mark’s study reviewing the UC surveillance program over approxi-
mately three decades, a total of 74 patients (12.3% of the total population) developed
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senting after a negative index-colonoscopy or advanced (Dukes’ C/disseminated)
cancers detected at surveillance.” During a median follow-up of 1.5 years, nine pa-
tients were identified with Dukes’ C cancers and four patients with disseminated can-
cers (4 of these 13 cases were diagnosed within 12 months). In three cases, CRC was
diagnosed at colonoscopy because of symptoms; one of these was attributable to
noncompliance. Of note, more than half (16 out of the 30) of the CRCs identified
with this program were interval cancers, raising concerns about the effectiveness of
colonoscopic cancer prevention. A statistically significant reduction in CRC rates
over time was observed in this study (r 5 0.40; P 5 .04), especially in the proximal
colon.
From these data, we can conclude that there is sparse understanding of the magni-
tude and clinical significance of interval CRCs in patients with IBD. Indeed, a wide vari-
ation exists with regard to the terminology used in endoscopy and pathology
diagnostic protocols across countries, IBD centers, and studies.
Standardization of the nomenclature and clinical protocols, and uniformity in report-
ing on interval CRCs during IBD surveillance, would help to define quality targets. As a
first step, a universal terminology is required for dysplasia and interval cancers. Pre-
viously used terms, such as flat dysplasia or dysplasia associated lesion or mass,
need to be revisited. A rigorous description of the endoscopic shape and histologic
features of the detected lesions is required, using international classifications (ie,
Paris-Japanese endoscopic classifications18,19 and the World Health Organization
histopathologic classifications20,21). Interval cancers should be considered those inva-
sive cancers diagnosed after a negative screening examination, but before the next
recommended follow-up colonoscopy, as endorsed by the current international IBD
surveillance guidelines.POTENTIAL ETIOLOGIC FACTORS OF INTERVAL CRCS
Similarly to sporadic CRCs, most interval CRCs in IBD probably can be explained by
clinician-dependent factors, such as missed, incompletely resected lesions or devia-
tion from surveillance protocols. The understanding of the underpinnings of such inter-
val CRCs is of importance because it may permit identification of modifiable factors,
for example gaps in knowledge and training on the recognition of nonpolypoid neo-
plasms and their endoscopic resection. In this case, tailored educational programs
would improve the awareness and help to shape practical skills, to ultimately safe-
guard the quality of colonoscopy. Furthermore, it is important to understand whether
certain molecular features of the inflamed mucosa could augment the risk of cancer
progression. Such information may help to develop personalized (ie, molecular-
based) surveillance strategies.
Missed Lesions
Two recent studies exploring the cause of sporadic interval CRCs in the general
population found missed lesions represent by far the most important contributor
(>50% of all interval CRCs).22,23 Undoubtedly, missed lesions are likely to account
for a significant proportion of interval CRCs in IBD, although a thorough analysis using
structured algorithms24 has not yet been performed. A recent population-based anal-
ysis by Wang and colleagues,25 using SEER cancer registry data from 55,008 older
patients with CRC, found rates of early/missed CRCs were three-fold greater in IBD
than in patients without IBD (15.1% for Crohn’s disease, 15.8% for UC vs 5.8% for pa-
tients without IBD; P<.001). Early/missed CRCs were defined as CRCs identified
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This study was based on administrative data, and therefore lacked detail about the
completeness of colonoscopy, bowel preparation, extent of colitis, characteristics
of mucosal lesions identified at the baseline examination, and resection outcomes.
Such observations underscore the importance of meticulous inspection of the entire
colonic mucosa, which should be ideally clean and free of inflammation, and the
need for formal training of the endoscopist in the recognition of IBD neoplasms. Pres-
ence of active or chronic background inflammation and the diversity in endoscopic
appearance of dysplasia by IBD may, however, increase the complexity of diagnosis.
Fig. 1 illustrates a lateral spreading tumor of granular subtype, which could have been
missed at a previous examination.
A substantial number of studies demonstrated that indigo carmine– or methylene
blue–guided chromoendoscopy (CE) improves the diagnostic yield of dysplasia andFig. 1. (A–D) Lateral spreading tumor of granular type, located in the descending colon of a
patient with a Crohn’s pancolitis. (E) Histopathology revealed low-grade dysplasia (Hema-
toxylin and eosin, original magnification 20). (F) Colonoscopic examination 8 months
earlier showed Mayo 2 inflammation only at the same anatomic site (arrows), suggesting
this lesion could have been missed.
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portion26–28 of dysplastic lesions in patients with IBD appear to have a flat appear-
ance, as illustrated in Table 1. Pancolonic CE delineates the borders and permits a
detailed analysis of the epithelial surface, thus facilitating the diagnosis of subtle le-
sions and their endoscopic resection. A few meta-analyses now demonstrate CE
with targeted biopsies is superior to white-light colonoscopy with random biopsies
in the detection of dysplasia and invasive CRCs.29–31 CE yielded a 7% increase in
the detection of any dysplasia.31 Compared with white-light colonoscopy with random
biopsies, the likelihood to detect any dysplasia with CE and targeted biopsies was 8.9-
fold greater, and 5.2-fold greater for detecting nonpolypoid dysplasia. In a Mainz study
of 165 patients with long-standing UC who were randomized to undergo standard co-
lonoscopy using white light versus CE (0.1%methylene blue), significantly more intra-
epithelial neoplasms were detected in the CE group (32 vs 10; P5 .003). CE detected
more intraepithelial neoplasms in “flat mucosa” than white-light endoscopy (24 vs 4;
P 5 .0007), and more invasive cancers (3 vs 1).26
In these studies, colonoscopies were performed by dedicated colonoscopists with
expertise in multimodal imaging, and under controlled circumstances (ie, clinical tri-
als), and may preclude generalizability. Recognition of the nonpolypoid dysplasia in
a real-world environment remains challenging and requires additional training. In a
study conducted at Maastricht University Medical Center, where the endoscopists
have been trained on the recognition of nonpolypoid neoplasms,32 the overall detec-
tion rate of sporadic NP-CRNs (defined as lesions of which the height was less than
half of the diameter) was 5.7% (diagnostic subgroup, 4.7%; screening subgroup,
4.5%; surveillance subgroup, 15.6%).33 The learning-curve in the detection of
NP-CRNs is, however, tedious, with at least 600 colonoscopies being required to
achieve a detection rate of at least 4.5%.34
It is highly likely that missed lesions have a major contribution to the development of
interval CRCs in patients with IBD, although this needs further investigation. The cur-
rent data highlight the importance of vigilant inspection and a thorough phenotyping of
lesions identified at colonoscopy, including subtle erosions, shallow ulcerations, and
their relationship with inflammation or strictures. Such exquisite detail may improve
the understanding of the link between inflammation, the occurrence of dysplasia,
and interval CRCs. High-quality videos/photodocumentation obtained in a standard-
ized fashion facilitates this process. Challenging cases should be performed by expert
endoscopists.
Incompletely Resected Lesions
Endoscopic resection of neoplasms in the context of colitis is clearly fraught with dif-
ficulties because of the presence of inflammation and scarring. Such conditions chal-
lenge the accurate detection, clear demarcation, and lifting of the lesions. Studies
examining the diagnostic yield of CE during surveillance for IBD provided, however,
limited information about the effectiveness of the endoscopic resection, which re-
quires further investigation. In a long-term follow-up evaluation, Odze and col-
leagues35 compared the outcome after polypectomy among three subgroups: (1)
patients with UC with adenoma-like dysplastic lesions, (2) patients with UC with spo-
radic adenomas, and (3) a non-UC sporadic adenoma subgroup. Prevalence of polyp
formation on follow-up, albeit high in this study, did not significantly differ across sub-
groups (62.5%, 50%, and 49%, respectively) indicating IBD-associated dysplasia may
be effectively treated endoscopically. Indeed, over the past few years, endoscopic
mucosal resection and endoscopic submucosal dissection resection techniques
proved to be increasingly safe and effective in the Western practice.36–38 A study
Table 1
Detection of flat dysplastic lesions in patients undergoing surveillance for IBD
Study, Author, Year Design
Endoscopist
Experience
Number of
Patients Dye
Number of Patients
with IEN
Flat Dysplastic
Lesions (Numbers)
Invasive CRCs
(Numbers)
Kiesslich et al,26 2003 Randomized 1:1, CE
vs standard WLE
Several experienced
endoscopists
165 MB 0.1% CE group: 32 IENs in
13 pts
WLE group: 10 IENs in
6 pts
CE group: 24
WLE group: 4
(P 5 .0007)
CE group: 3 invasive
CRC
WLE group: 1
invasive CRC
Matsumoto et al,27
2003
Prospective
cohort CE
Single experienced
endoscopist
57 IC 0.2% 12 pts with 117 IENs 27 4 HGD/invasive CRCs
Rutter et al,28 2004 Prospective cohort
back-to-back
WLE/CE
Single experienced
endoscopist
100 IC 0.1% CE group: 9 pts
WLE group: 2 pts
CE group: 75 “flat
topped elevated”
WLE group: 0
None
Kiesslich et al, 2007 Randomized 1:1
CE (N 5 80) vs WLE
(N 5 73)
Several experienced
endoscopists
153 MB 0.1% CE group: 19 in 11 pts
CC group: 4 in 4 pts
CE group: 16
CC group: 2
None
Hlavaty et al, 2011 Tandem
colonoscopies
Several experienced
endoscopists
30 IC 0.4% WLE: 2
CE: 4
2 None
Gu¨nther et al, 2011 Randomized
Group 1: random
biopsies; Group 2
CE 1 biopsies;
Group 3 CE 1
confocal
endomicroscopy
Two experienced
endoscopists
150 IC 0.1% Group 1: no IEN
Group 2: 2 pts
Group 3: 4 pts
Group I (0)
Group II (18)
Group III (10)
1 (Group 3)
Abbreviations: CC, conventional colonoscopy; HGD, high-grade dysplasia; IC, indigo carmine; MB, methylene blue; WLE, white-light endoscopy.
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Interval CRC in IBD 343examining the effectiveness of endoscopic resection of NP-CRNs found that 93% of
those larger than 10 mm were successfully resected.36 Residual neoplasia was iden-
tified in 10% of cases on the first follow-up examination, although complete resection
was obtained in all cases after one to three follow-up examinations. Likewise, Buchner
and colleagues37 found that large sessile and NP-CRNs could bemanaged endoscop-
ically in 91% of cases, with a perforation rate of 0.4% and a bleeding rate of 11%.
Because 9%23 to 50%38 of the sporadic interval CRCs are thought to be caused by
an ineffective polyp resection, the precise contribution of this factor to the genesis
of interval CRCs in patients with IBD needs further elucidation.
Adherence to Colonoscopic Surveillance
Adherence to colonoscopic surveillance guidelines is indeed vital, but seems to be
often problematic.39–42 There are several caveats to keep in mind, foremost of which
is the patient’s understanding of the cancer risk.43,44 Disease flares and presence of
comorbidity may further reduce the compliance to surveillance. Because the presence
of disease activity challenges the endoscopic and histologic appreciation of dysplasia,
colonoscopic surveillance should be ideally performed in the quiescent phase. How-
ever, surveillance should not be delayed too long, because those with more active
disease carry a greater risk of developing CRC. With regard to bowel preparation, a
low-residue diet the days before the procedure in conjunction with split-dose polyeth-
ylene glycol solutions is often sufficient for adequate cleansing, without inducing
inflammation.
Biologic Features
The precise biologic events underlying chronic inflammation and leading to a faster
progression to CRC are presently unknown and need further exploration. A subset
of dysplastic lesions identified in patients with IBD harbor a villous phenotype, as illus-
trated in Fig. 2. Such macroscopic features have been suggested to represent a red
flag for the presence of invasive CRC, especially of colloid subtype.45 Other CRCs har-
bor signet ring cells, features associated with a more aggressive biologic behavior.
Fig. 3 illustrates a small signet ring cell carcinoma that displayed clear signs of local
invasion. Approximately 6% of the cancers in patients with IBD are small flat invasive
CRCs, without adjacent adenomatous tissue,30 suggesting that progression to CRC
may involve a pathway different from the classic adenoma-carcinoma sequence.Fig. 2. (A–C) Lateral spreading tumor of the rectum in a patient with distal ulcerative colitis.
Examination using high-definition endoscopy in conjunction with chromoendoscopy clearly
showed a villous appearance. (D) Histopathology revealed low-grade dysplasia (Hematoxy-
lin and eosin, original magnification 20). (E) Fuller view of lesion with indigo carmine
chromoendoscopy.
Fig. 3. (A) A 10-mm sized, Paris type IIa1IIc lesion, with a central ulceration that has been
identified at the hepatic flexure of a patient with Crohn’s colitis. (B) Examination of the sur-
gical specimen showed the small cancer (arrows). (C) Histopathology revealed a poorly
differentiated signet ring cell adenocarcinoma, with signs of lymphangioinvasion. The
lesion was located near a stricture (Hematoxylin and eosin, original magnification 30)
(D, E) and staged pT3N1Mx.
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CRCs in patients with IBD.46 Interestingly, a recent study by Voorham and col-
leagues47 found that sporadic nonpolypoid neoplasms are likely to herald 5q loss,
and less likely MSI and APC mutations, features resembling the carcinogenesis pro-
cess in inflammatory conditions, such as IBD.
In summary, clinician-dependent factors and biologic factors intermingle in the gen-
esis of interval CRCs by IBD. It is important to understand whether presence of NP (flat
or depressed)-CRNs in patients with IBD signifies a diagnostic and therapeutic chal-
lenge alone. The most effective filter of missed or incompletely resected lesions would
then be training for improving the education and endoscopic skills. Clinical decisional
algorithms, including the characterization of shape, epithelial surface of lesions, and
their relation with inflammation,31 have the potential to steer the diagnostic and ther-
apeutic process and optimize outcomes. If a subset of the NP-CRNs contains molec-
ular features associated with a greater risk of CRC, such patients need to be identified
and closely surveyed to prevent CRC.
CONCLUDING REMARKS
Interval CRCs may account for approximately 50% of the CRCs identified during IBD
surveillance, favoring the idea that clinical consent should include information about
cancer risk. Improvements in the quality of colonoscopic examinations are vital for
minimizing the CRC risk of patients with IBD. Box 1 summarizes basic concepts for
achieving that goal. Standardization of clinical protocols is required, including the
use of high-definition and high-resolution colonoscopes coupled with the application
of pancolonic CE with targeted biopsies. Surveillance colonoscopy using white light
with random biopsies should be abandoned. Formal training in recognition of NP-
CRNs and proficiency in endoscopic resection techniques should be compulsory
for providers who perform surveillance in patients with IBD. Comprehensive colonos-
copy and pathology data reporting using a standardized nomenclature and interpre-
tation of findings using tailored algorithms may ultimately shed light on the cause of
interval CRCs and the required improvements.
Box 1
Principles for quality colonoscopy during surveillance for IBD: The Six Ts
 Timing
Ideally, surveillance should be performed in the quiescent phase.
 Tolerance
Tolerance of bowel preparation is key for adequate cleansing; a low-residue diet can be
added to standard split-dose bowel preparations.
 Technology
High-definition/high-resolution colonoscopes should be used.
 Technique
Pancolonic chromoendoscopy with targeted biopsies should be considered the standard of
care.
 Training
The IBD specialist and pathologist needs to be formally trained on detection, classification,
and diagnosis of nonpolypoid (flat or depressed) colorectal neoplasms.
 Traits
A thorough registration of patient and lesion characteristics may help identify the most
likely cause:
 Patient with IBD: duration and extent of disease, presence of primary sclerosing
cholangitis, family history of CRC, personal history of colorectal polyps (including
postinflammatory polyps), history of medication, compliance and response to therapy
 Lesions at baseline examination: location, size, shape, histology, and the relationship
with inflammation and strictures
 Interval CRCs: recommended surveillance intervals, time to CRC diagnosis, location of
tumor, histology, and tumor stage
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